Nocturne Acquisition Corp is a United States-based company. The Company is a shell company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The Company has no operations and has not generated revenues.

Employees

Sector

Investment Holding Companies

More about the company

Market Closed - Nasdaq 21:00:00 03/04/2024 BST			5-day change	1st Jan Change
11.66 ^USD	-0.49%		-.--%	-

02/04/24	Nocturne Acquisition Corporation(NasdaqCM:MBTC) dropped from NASDAQ Composite Index	CI
30/03/24	Cognos Therapeutics Inc. cancelled the acquisition of Nocturne Acquisition Corporation from a group of shareholders in a reverse merger transaction.	CI

Market Cap	60.48M 53.07M 50.12M 45.68M 85.51M 5.8B 86.12M 600M 232M 2.96B 227M 222M 9.52B	P/E 2021	-163x	P/E 2022	-78.5x
Enterprise Value	64.05M 56.21M 53.08M 48.38M 90.56M 6.14B 91.21M 635M 246M 3.14B 240M 235M 10.08B	EV / Sales 2021	-	EV / Sales 2022	-
Free-Float	23.5%	Yield 2021 *	-	Yield 2022	-

02/04/24	Nocturne Acquisition Corporation(NasdaqCM:MBTC) dropped from NASDAQ Composite Index	CI
30/03/24	Cognos Therapeutics Inc. cancelled the acquisition of Nocturne Acquisition Corporation from a group of shareholders in a reverse merger transaction.	CI
07/02/24	Nocturne Acquisition Corporation Announces Management Changes	CI
05/02/24	Nocturne Acquisition Shares Jump as Stockholders' Vote on Merger With Cognos Therapeutics Postponed Further	MT
22/11/23	Nocturne Acquisition Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
21/08/23	Nocturne Acquisition Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
23/06/23	Nocturne Acquisition Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
26/05/23	Nocturne Acquisition Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	CI
25/05/23	Nocturne Acquisition Corporation Auditor Raises 'Going Concern' Doubt	CI
03/01/23	Nocturne Acquisition in Deal to Merge With Cognos Therapeutics	MT
02/01/23	Cognos Therapeutics Inc. executed a definitive business combination agreement to acquire Nocturne Acquisition Corporation from Nocturne Sponsor, LLC, Polar Asset Management Partners Inc., Periscope Capital Inc, Sea Otter Advisors LLC and others for approximately $120 million in a reverse merger transaction.	CI
21/11/22	Nocturne Acquisition Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
22/08/22	Nocturne Acquisition Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI

20/09/23	Chardan Engaged to Facilitate Nocturne Acquisition Corporation's Business Combination with Cognos Therapeutics, Inc., Paving the Way for NASDAQ Listing	AQ
02/05/23	NOCTURNE ACQUISITION CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
14/04/23	NOCTURNE ACQUISITION CORP : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
06/04/23	NOCTURNE ACQUISITION CORP : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	AQ
03/04/23	NOCTURNE ACQUISITION CORP : Regulation FD Disclosure (form 8-K)	AQ

Cognos Therapeutics Holdings, Inc. Share Price

Stocks

MBTC

KYG6580S1140

Investment Holding Companies

Valuation: Cognos Therapeutics Holdings, Inc.

Latest news: Cognos Therapeutics Holdings, Inc.

Press Releases: Cognos Therapeutics Holdings, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Cognos Therapeutics Holdings, Inc.

Latest insider transactions

Shell Companies

Financials

Company Profile

Manager	Title	Age	Since
Henry Monzon CEO	Chief Executive Officer	52	27/10/2020
Ka Seng Ao DFI	Director of Finance/CFO	37	27/10/2020
Haoyu Lin PRN	Corporate Officer/Principal	37	01/02/2024

Director	Title	Age	Since
Henry Monzon CHM	Chairman	52	27/10/2020
Ka Seng Ao BRD	Director/Board Member	37	27/10/2020
Hon Keung Choi BRD	Director/Board Member	65	15/12/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
02/02/24	Nocturne Sponsor LLC	Other	Company	3,340,000	27.9148%
14/04/21	Nocturne Sponsor LLC	Buy	Company	15,000	0.1435%
14/04/21	Nocturne Sponsor LLC	Buy	Company	15,000	0.1435%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
COGNOS THERAPEUTICS HOLDINGS, INC.	-0.49%	-.--%	-.--%	+1.92%	56.65M
CHURCHILL CAPITAL CORP XI	+1.64%	-3.64%	-	-	681M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	+0.10%	-0.10%	-	-	647M
BAIN CAPITAL GSS INVESTMENT CORP.	+0.19%	+0.19%	-	-	601M
CHURCHILL CAPITAL CORP XII	+0.65%	+1.36%	-	-	595M
CANTOR EQUITY PARTNERS IV, INC.	+0.15%	-0.39%	+1.28%	-	588M
CENTIEL AG	+0.68%	-6.29%	+279.62%	-73.63%	583M
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	-0.27%	+0.45%	+11.60%	-	553M
NEW AMERICA ACQUISITION I CORP.	0.00%	-0.10%	-	-	501M
Average	+0.29%	-0.67%	+73.12%	-35.85%	534.02M
Weighted average by Cap.	+0.41%	-0.85%	+95.52%	-66.93%

	2021	2022
Net sales	-	-
Net income	-710K -623K -589K -536K -1M -68.06M -1.01M -7.04M -2.73M -34.77M -2.67M -2.61M -112M	-1.21M -1.06M -1M -913K -1.71M -116M -1.72M -11.98M -4.64M -59.16M -4.54M -4.44M -190M
Net Debt	-385K -337K -319K -290K -544K -36.85M -547K -3.81M -1.48M -18.83M -1.44M -1.41M -60.51M	3.57M 3.14M 2.96M 2.7M 5.05M 342M 5.09M 35.43M 13.72M 175M 13.41M 13.12M 562M

3 years	9.45	13.98
5 years	9.45	13.98
10 years	9.45	13.98